Revance Therapeutics Sees Unusually High Options Volume (NASDAQ:RVNC)

Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) was the target of unusually large options trading activity on Monday. Stock investors acquired 19,249 call options on the company. This is an increase of 445% compared to the typical volume of 3,535 call options.

Analyst Ratings Changes

Several research firms have commented on RVNC. Needham & Company LLC lifted their target price on shares of Revance Therapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, January 10th. Morgan Stanley lowered their target price on shares of Revance Therapeutics from $27.00 to $25.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 9th. Guggenheim lifted their target price on shares of Revance Therapeutics to $36.00 in a research note on Tuesday, November 15th. Barclays lifted their price target on shares of Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Wednesday, November 16th. Finally, StockNews.com lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.20.

Insider Transactions at Revance Therapeutics

In other news, CFO Tobin Schilke sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $31.00, for a total transaction of $31,000.00. Following the completion of the transaction, the chief financial officer now directly owns 57,877 shares of the company’s stock, valued at approximately $1,794,187. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Revance Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Waypoint Capital Advisors LLC acquired a new position in Revance Therapeutics in the 4th quarter worth $997,000. Allspring Global Investments Holdings LLC boosted its stake in Revance Therapeutics by 86.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,094,524 shares of the biopharmaceutical company’s stock valued at $20,205,000 after purchasing an additional 508,249 shares during the period. DNB Asset Management AS acquired a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $218,000. California State Teachers Retirement System lifted its stake in shares of Revance Therapeutics by 10.9% in the 3rd quarter. California State Teachers Retirement System now owns 97,856 shares of the biopharmaceutical company’s stock worth $2,642,000 after acquiring an additional 9,642 shares during the period. Finally, Glenmede Trust Co. NA acquired a new stake in Revance Therapeutics during the third quarter valued at approximately $300,000. Institutional investors and hedge funds own 82.68% of the company’s stock.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $33.51 on Tuesday. The company has a current ratio of 5.56, a quick ratio of 5.33 and a debt-to-equity ratio of 2.60. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -8.55 and a beta of 0.57. The firm’s fifty day simple moving average is $22.72 and its 200 day simple moving average is $22.24. Revance Therapeutics has a twelve month low of $11.27 and a twelve month high of $34.22.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.32). The business had revenue of $29.02 million for the quarter, compared to analyst estimates of $28.76 million. Revance Therapeutics had a negative net margin of 251.92% and a negative return on equity of 461.54%. As a group, equities research analysts expect that Revance Therapeutics will post -4.32 earnings per share for the current fiscal year.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.